Centro de Investigación Biomédica en Red sobre Enfermedades Raras -ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2024

  1. AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

    Science advances, Vol. 10, Núm. 41, pp. eadn6525

  2. Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model

    Biomedical Journal, Vol. 47, Núm. 4

  3. Therapeutic potential of oleic acid supplementation in myotonic dystrophy muscle cell models

    Biological Research, Vol. 57, Núm. 1

2023

  1. CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2

    Molecular Therapy - Nucleic Acids, Vol. 31, pp. 324-338

  2. Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice

    Scientific Reports, Vol. 13, Núm. 1